Confirm suitability and preparation
Ask a qualified professional whether the test fits your situation and follow the instructions supplied for the confirmed collection appointment.
Loading page
SeroMark-1 is a blood-based biomarker test designed to add information to prostate cancer risk assessment alongside PSA. This guide explains what it means in clear, practical language.
Screening aid only · Not a diagnosis · Doctor interpretation required
More than one number. Always interpreted in clinical context.
The test looks at several serum phospholipid biomarker signals and combines them into a structured risk index. It is intended to support a clinical conversation, not provide a standalone answer.
One or more of these situations may be a reason to discuss SeroMark-1. A qualified healthcare professional should confirm final suitability for each person.
PSA remains an established part of prostate assessment. SeroMark-1 is designed to add molecular risk information rather than replace PSA, examination, imaging, biopsy, or doctor judgement.
| Question | PSA | SeroMark-1 |
|---|---|---|
| What it measures | The amount of prostate-specific antigen in blood | A profile of multiple serum phospholipid biomarker signals |
| What it provides | A PSA value that needs clinical interpretation | An additional molecular risk index for clinical review |
| Clinical role | An established part of prostate assessment | Complementary information alongside PSA and other findings |
| What it does not do | A PSA value alone does not diagnose cancer | A SeroMark-1 result does not diagnose or exclude cancer |
The collection team should give you the final preparation instructions. Contact Nutech before travelling if your location or appointment has not been confirmed.
Ask a qualified professional whether the test fits your situation and follow the instructions supplied for the confirmed collection appointment.
A trained professional collects a routine venous blood sample. The serum is prepared and transported through the approved route.
The laboratory evaluates the serum phospholipid biomarker profile and processes the signals through the predictive model.
Your healthcare professional interprets the risk band with your history, PSA, examination, and any other appropriate findings.
The index must be interpreted with your broader clinical information. A band does not confirm or exclude prostate cancer.
0.00–0.34
A lower index within the defined SeroMark-1 scale. Continue the screening and follow-up plan recommended by your doctor.
0.35–0.49
An intermediate index that needs careful review with your PSA, history, examination, and other relevant findings.
0.50–1.00
A higher index that may lead to prompt clinical review so your doctor can decide whether further evaluation is appropriate.
Do not change treatment, miss follow-up, or delay medical care because of an online explanation or a screening result.
These answers provide general information. Your healthcare professional and confirmed collection route provide the final instructions for your situation.
View the complete FAQNo. It is a screening aid that provides additional risk information. A diagnosis requires an appropriate doctor-led evaluation and may involve other tests, imaging, or biopsy.
No. It is designed to complement PSA and the wider clinical assessment, not replace them.
Not necessarily. Screening is discussed before symptoms appear. New, persistent, or concerning symptoms should be assessed directly by a healthcare professional.
Nutech's current workflow describes fasting collection. Follow the exact preparation instructions provided for your confirmed appointment because requirements may vary when other tests are collected at the same time.
No. A low result does not make cancer impossible and should never be used to ignore symptoms or miss follow-up recommended by your doctor.
Nutech will help confirm suitability, current collection access, preparation instructions, and the appropriate route. Do not travel until an appointment and location have been confirmed.